Eloxx Pharmaceuticals annual ebitda
2010
2011
2012
2013
2014
2015
2016
2017
Eloxx Pharmaceuticals EBITDA Growth & History (ELOX)
Eloxx Pharmaceuticals's calculated EBITDA was −$4.5M for fiscal 2017.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2017 · Jun 30 | 2017-06-30 | −$4.5M | $6.6M | — |
| 2016 | 2016-06-30 | −$11.1M | $6.8M | — |
| 2015 | 2015-06-30 | −$17.9M | −$9.1M | — |
| 2014 | 2014-06-30 | −$8.8M | −$4.4M | — |
| 2013 | 2013-06-30 | −$4.4M | $796,634 | — |
| 2012 | 2012-06-30 | −$5.2M | $2.6M | — |
| 2011 | 2011-06-30 | −$7.8M | −$3.1M | — |
| 2010 | 2010-06-30 | −$4.7M | — | — |
Eloxx Pharmaceuticals quarterly ebitda
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q1 2018 · Sep 30 | 2017-09-30 | −$4.0M | −$1.8M | — |
| Q4 2017 | 2017-06-30 | $1.8M | $3.2M | — |
| Q3 2017 | 2017-03-31 | −$2.6M | $2.2M | — |
| Q2 2017 | 2016-12-31 | −$1.5M | $2.2M | — |
| Q1 2017 | 2016-09-30 | −$2.2M | −$1.1M | — |
| Q4 2016 | 2016-06-30 | −$1.4M | −$502,801 | — |
| Q3 2016 | 2016-03-31 | −$4.9M | −$3.7M | — |
| Q2 2016 | 2015-12-31 | −$3.7M | $7.0M | — |
| Q1 2016 | 2015-09-30 | −$1.1M | $4.0M | — |
| Q4 2015 | 2015-06-30 | −$880,909 | $2.7M | — |
| Q3 2015 | 2015-03-31 | −$1.2M | $857,003 | — |
| Q2 2015 | 2014-12-31 | −$10.7M | −$9.2M | — |
| Q1 2015 | 2014-09-30 | −$5.1M | −$3.4M | — |
| Q4 2014 | 2014-06-30 | −$3.6M | −$2.6M | — |
| Q3 2014 | 2014-03-31 | −$2.0M | −$1.1M | — |
| Q2 2014 | 2013-12-31 | −$1.5M | −$277,278 | — |
| Q1 2014 | 2013-09-30 | −$1.7M | −$495,355 | — |
| Q4 2013 | 2013-06-30 | −$968,308 | $525,684 | — |
| Q3 2013 | 2013-03-31 | −$972,783 | $69,433 | — |
| Q2 2013 | 2012-12-31 | −$1.2M | $161,272 | — |
| Q1 2013 | 2012-09-30 | −$1.2M | $40,245 | — |
| Q4 2012 | 2012-06-30 | −$1.5M | $1.3M | — |
| Q3 2012 | 2012-03-31 | −$1.0M | $289,342 | — |
| Q2 2012 | 2011-12-31 | −$1.4M | $75,554 | — |
| Q1 2012 | 2011-09-30 | −$1.2M | $948,273 | — |
| Q4 2011 | 2011-06-30 | −$2.8M | — | — |
| Q3 2011 | 2011-03-31 | −$1.3M | — | — |
| Q2 2011 | 2010-12-31 | −$1.5M | — | — |
| Q1 2011 | 2010-09-30 | −$2.2M | — | — |
Eloxx Pharmaceuticals ebitda trends
Over the last five reported fiscal years, Eloxx Pharmaceuticals's ebitda increased from −$5.2M to −$4.5M, a change of $604,711. The latest reported quarter, Q1 2018 · Sep 30, shows −$4.0M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eloxx Pharmaceuticals filings at SEC.gov ↗